Information Provided By:
Fly News Breaks for June 5, 2015
MNK
Jun 5, 2015 | 07:55 EDT
UBS hosted investors meetings with Mallinckrodt management and came away remaining confident in their investment thesis and saying it remains a solid name to own in specialty pharma. The firm cited confidence in management's ability to execute its strategy with cost cutting and further tax improvements. UBS reiterated its Buy rating and $141 price target on Mallinckrodt shares.
News For MNK From the Last 2 Days
There are no results for your query MNK